Semaglutide

GLP-1 receptor agonists

ATC code: A10BJ06

Brand names: Ozempic, Wegovy, Rybelsus

Updated 24 Sep 2026 · Methodology

Indications

Established ASCVD, secondary prevention

First line

Per 2023 and / 2024, in T2D patients with established atherosclerotic CVD, GLP-1 agonists (semaglutide, liraglutide, dulaglutide) and SGLT2 inhibitors are first-choice regardless of . MACE reduction is established in large RCTs (SUSTAIN-6, REWIND, LEADER).

In T2D patients with established atherosclerotic CVD.

Sources

ICD-10: I25 · ICD-11: BA5Z

Obesity

First line

Semaglutide 2.4 mg weekly (Wegovy in the US and EU) is approved for obesity in adults with BMI ≥ 30, or ≥ 27 with comorbidities. STEP-1 (1,961 patients) showed 14.9 % weight loss over 68 weeks vs 2.4 % on placebo. Wegovy is not registered in Russia; obesity treatment uses Ozempic off-label or Saxenda (liraglutide). Approved in adolescents 12–17 years with obesity per STEP-Teens. Benefits persist only with continued therapy – two thirds of weight returns within a year after discontinuation.

Sources

ICD-10: E66 · ICD-11: 5B81

Type 2 diabetes mellitus

First line

Per 2024 and 2022, semaglutide is first-line in T2D with established CVD, HF, or CKD, especially when weight loss is needed. Subcutaneous start: 0.25 mg weekly for 4 weeks, then 0.5 mg, escalating to 1.0 or 2.0 mg if needed. SUSTAIN-6 (3,297 patients) showed a 26 % reduction in MACE in T2D patients at high CV risk.

Sources

ICD-10: E11 · ICD-11: 5A11

Weight loss in patients without obesity or overweight

Individual decision

Semaglutide does genuinely reduce weight, but in people without obesity and without overweight (BMI under 27) and without metabolic indications this use is unwise and not supported by international guidelines. The approved indication is obesity (BMI >=30, or >=27 with comorbidities), covered on a separate card. Cosmetic use carries real risks (nausea and vomiting, acute pancreatitis risk, gallstones, a class warning for medullary thyroid cancer) and financial burden, and the effect is not durable - weight returns after stopping. Weight loss in people without obesity is more safely built on diet, activity, and sleep.

In patients without obesity or metabolic comorbidities.

Sources

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Anti-aging and longevity

Not recommended

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is prescribed for type 2 diabetes (Ozempic) and for obesity or overweight with comorbidities (Wegovy) ( 2024, AACE 2023, EASO 2023). In anti-aging and longevity circles, semaglutide is promoted as a drug for metabolic rejuvenation in people with normal weight and without diabetes. In people without diabetes and without overweight (BMI below 27 kg/m²), no clinical studies of prophylactic use exist. The drug has serious risks: GI disturbances (nausea, vomiting, diarrhea in 30–40%), pancreatitis, medullary thyroid cancer risk ( boxed warning in MEN-2 patients), cholelithiasis, potential depression, and severe muscle atrophy with rapid weight loss. If semaglutide was prescribed to a person with normal weight and without diabetes, consider seeking a second opinion.

Sources

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Selective GLP-1 receptor agonist. Stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon, slows gastric emptying, and enhances satiety centrally. Reduces by 1.5–1.8 % and body weight by 5–15 % depending on dose and indication. Improves cardiovascular outcomes in T2D with established CVD. In obesity without diabetes (Wegovy 2.4 mg weekly), weight loss reaches 15 % over 68 weeks.

Safety

Boxed warning

FDA boxed warning: increased risk of thyroid C-cell tumors (medullary cancer) in rodents. Causal link in humans is unconfirmed, but the drug is contraindicated in personal or family history of medullary thyroid cancer and MEN 2.

Contraindications

Personal or family history of medullary thyroid cancer
Multiple endocrine neoplasia type 2 (MEN 2)
Type 1 diabetes
History of acute pancreatitis
Pregnancy and breastfeeding
Hypersensitivity

Serious adverse effects

Acute pancreatitis
Euglycemic diabetic ketoacidosis (rare)
Acute cholelithiasis and cholecystitis
Fournier gangrene (very rare)
Acute kidney injury (with severe dehydration)
Worsening diabetic retinopathy

Common adverse effects

Nausea (15–20 % of patients, especially in early weeks)
Vomiting, diarrhea
Constipation
Decreased appetite
Abdominal pain
Eructation
Injection site reactions

Pregnancy: can you take Semaglutide?

Contraindicated in pregnancy. Discontinue at least 2 months before planned conception. In pregnant T2D, the standard is insulin, occasionally metformin in consultation with the endocrinologist.

Breastfeeding: can you take Semaglutide?

Contraindicated during breastfeeding per manufacturer label.

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Subcutaneous once weekly on the same day each week. Injection sites: abdomen, thigh, upper arm. Oral (Rybelsus) — once daily in the morning fasting, with up to 120 mL water; no food or drink for at least 30 minutes after. For a missed injection: take within 5 days if at least 48 hours remain to the next dose; otherwise skip and continue on schedule.

Monitoring

At baseline and regularly: (in T2D), body weight, BP, eGFR. With nausea, vomiting, or abdominal pain — rule out acute pancreatitis (amylase, lipase). In patients with retinopathy — ophthalmology follow-up; rapid glycemic improvement can transiently worsen retinopathy. When switching from insulin or sulfonylureas to semaglutide, adjust those agents to prevent hypoglycemia.

Common myths

Myth: 'Ozempic is for everyone who wants to lose weight'. Fact: semaglutide is registered for T2D and obesity (BMI ≥ 30, or ≥ 27 with comorbidities). Without these indications, benefit does not outweigh risk.

Myth: 'semaglutide is safe to inject long-term without monitoring'. Fact: real side effects include nausea, vomiting, theoretical medullary thyroid cancer risk (rodent data, not confirmed in humans), acute pancreatitis, euglycemic ketoacidosis, and Fournier gangrene. Therapy requires medical supervision.

Myth: 'after stopping semaglutide, weight will not return'. Fact: studies show two thirds of lost weight returns within a year after discontinuation. Effective long-term obesity care requires continued therapy or sustained lifestyle change.

Label mentions14 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

Moderateinsulinclass named in the label
«Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin: When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as…»
FDA, section 7 · Open on DailyMed
ModerateInsulin
«General: No se debe utilizar semaglutida para el tratamiento de la cetoacidosis diabética. Semaglutida no es un sustituto de la insulina. Se ha notificado cetoacidosis diabética en pacientes…»
AEMPS, section 4.4 · Open on CIMA
Moderateinsulinaclass named in the label
«General: No se debe utilizar semaglutida para el tratamiento de la cetoacidosis diabética. Semaglutida no es un sustituto de la insulina. Se ha notificado cetoacidosis diabética en pacientes…»
AEMPS, section 4.4 · Open on CIMA
Moderatesulfonilureasclass named in the label
«Hipoglucemia: Los pacientes tratados con semaglutida en combinación con una sulfonilurea o insulina podrían presentar un riesgo mayor de hipoglucemia. Es posible disminuir el riesgo de hipoglucemia…»
AEMPS, section 4.4 · Open on CIMA
Moderatesulfonylureasclass named in the label
«Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin: When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as…»
FDA, section 7 · Open on DailyMed
MinorParacetamol
«Paracetamol: Semaglutida retrasa la velocidad de vaciamiento gástrico tal como determinó la farmacocinética de paracetamol durante una prueba de comida estándar. El AUC 0–60 min y la C máx de…»
AEMPS, section 4.5 · Open on CIMA
anticonceptivos hormonalesclass named in the label
«Anticonceptivos orales: No se prevé que semaglutida disminuya el efecto de los anticonceptivos orales, ya que semaglutida no modificó de una forma clínicamente significativa la exposición general de…»
AEMPS, section 4.5 · Open on CIMA
Atorvastatin
«Atorvastatina: Semaglutida no modificó la exposición general de atorvastatina tras la administración de una dosis única de atorvastatina (40 mg). La C máx de atorvastatina se redujo en un 38%. Se…»
AEMPS, section 4.5 · Open on CIMA
Digoxin
«Digoxina: Semaglutida no modificó la exposición general ni la C máx de digoxina tras la administración de una dosis única de digoxina (0,5 mg).»
AEMPS, section 4.5 · Open on CIMA
Ethinylestradiol
«Anticonceptivos orales: No se prevé que semaglutida disminuya el efecto de los anticonceptivos orales, ya que semaglutida no modificó de una forma clínicamente significativa la exposición general de…»
AEMPS, section 4.5 · Open on CIMA
Levonorgestrel
«Anticonceptivos orales: No se prevé que semaglutida disminuya el efecto de los anticonceptivos orales, ya que semaglutida no modificó de una forma clínicamente significativa la exposición general de…»
AEMPS, section 4.5 · Open on CIMA
Metformin
«Metformina: Semaglutida no modificó la exposición general ni la C máx de metformina tras la administración de 500 mg de metformina dos veces al día durante 3,5 días.»
AEMPS, section 4.5 · Open on CIMA
Warfarin
«Warfarina y otros derivados de la cumarina: Semaglutida no modificó la exposición general ni la C máx de los enantiómeros R y S de warfarina tras la administración de una dosis única de warfarina (25…»
AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

ModerateLevothyroxine sodium
«Semaglutida: La administración concomitante de semaglutida puede afectar la exposición a levotiroxina. La exposición total (AUC) de tiroxina (ajustada por niveles endógenos) aumentó en un 33% después…»
AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Semaglutide used for?

Semaglutide is evaluated for the following indications with varying evidence strength: Established ASCVD, secondary prevention (evidence tier A), Obesity (evidence tier A), Type 2 diabetes mellitus (evidence tier A). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Semaglutide?

Common side effects of Semaglutide (≥ 1 in 100): Nausea (15–20 % of patients, especially in early weeks), Vomiting, diarrhea, Constipation, Decreased appetite, Abdominal pain, Eructation. See the Safety section for uncommon and serious reactions.

Is Semaglutide safe during pregnancy?

Contraindicated in pregnancy. Discontinue at least 2 months before planned conception. In pregnant T2D, the standard is insulin, occasionally metformin in consultation with the endocrinologist.

Is Semaglutide compatible with breastfeeding?

Contraindicated during breastfeeding per manufacturer label.

Who should not take Semaglutide?

Semaglutide is contraindicated in: Personal or family history of medullary thyroid cancer; Multiple endocrine neoplasia type 2 (MEN 2); Type 1 diabetes; History of acute pancreatitis; Pregnancy and breastfeeding. Full list in the Safety section.

Does Semaglutide carry an FDA boxed warning?

Ozempic is for everyone who wants to lose weight

semaglutide is registered for T2D and obesity (BMI ≥ 30, or ≥ 27 with comorbidities). Without these indications, benefit does not outweigh risk.

semaglutide is safe to inject long-term without monitoring

real side effects include nausea, vomiting, theoretical medullary thyroid cancer risk (rodent data, not confirmed in humans), acute pancreatitis, euglycemic ketoacidosis, and Fournier gangrene. Therapy requires medical supervision.

after stopping semaglutide, weight will not return

studies show two thirds of lost weight returns within a year after discontinuation. Effective long-term obesity care requires continued therapy or sustained lifestyle change.

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMA
EMALabel dated 01/06/2022
FDA / DailyMedLabel dated 07/30/2026

Other drugs in this group

Sitagliptin, Sitagliptin + Metformin, Tirzepatide, Vildagliptin, Gliclazide, Insulin detemir, Linagliptin, Vildagliptin + Metformin